Author:
Nguyen Van Phuc,Hu Justin,Zhe Josh,Chen Eugene Y.,Yang Dongshan,Paulus Yannis M.
Abstract
AbstractUsher syndrome type 2A (USH2A) is a genetic disorder characterized by retinal degeneration and hearing loss. To better understand the pathogenesis and progression of this syndrome, animal models such as USH2A knockout (USH2AKO) rabbits have been developed. In this study, we employed multimodal imaging techniques, including photoacoustic microscopy (PAM), optical coherence tomography (OCT), fundus autofluorescence (FAF), fluorescein angiography (FA), and indocyanine green angiography (ICGA) imaging to evaluate the retinal changes in the USH2AKO rabbit model. Twelve New Zealand White rabbits including USH2AKO and wild type (WT) were used for the experiments. Multimodal imaging was implemented at different time points over a period of 12 months to visualize the progression of retinal changes in USH2AKO rabbits. The results demonstrate that ellipsoid zone (EZ) disruption and degeneration, key features of Usher syndrome, began at the age of 4 months old and persisted up to 12 months. The EZ degeneration areas were clearly observed on the FAF and OCT images. The FAF images revealed retinal pigment epithelium (RPE) degeneration, confirming the presence of the disease phenotype in the USH2AKO rabbits. In addition, PAM images provided high-resolution and high image contrast of the optic nerve and the retinal microvasculature, including retinal vessels, choroidal vessels, and capillaries in three-dimensions. The quantification of EZ fluorescent intensity using FAF and EZ thickness using OCT provided comprehensive quantitative data on the progression of degenerative changes over time. This multimodal imaging approach allowed for a comprehensive and non-invasive assessment of retinal structure, microvasculature, and degenerative changes in the USH2AKO rabbit model. The combination of PAM, OCT, and fluorescent imaging facilitated longitudinal monitoring of disease progression and provided valuable insights into the pathophysiology of USH2A syndrome. These findings contribute to the understanding of USH2A syndrome and may have implications for the development of diagnostic and therapeutic strategies for affected individuals. The multimodal imaging techniques employed in this study offer a promising platform for preclinical evaluation of potential treatments and may pave the way for future clinical applications in patients with Usher syndrome.
Funder
National Institutes of Health
National Eye Institute
Fight for Sight-International Retinal Research Foundation
Publisher
Springer Science and Business Media LLC
Reference51 articles.
1. Toms, M., Pagarkar, W. & Moosajee, M. Usher syndrome: Clinical features, molecular genetics and advancing therapeutics. Therap. Adv. Ophthalmol. 12, 2515841420952194 (2020).
2. Boughman, J., Vernon, M. & Shaver, K. Usher syndrome: Definition and estimate of prevalence from two high-risk populations. J. Chronic Dis. 36, 595–603 (1983).
3. Ben-Rebeh, I. et al. Genetic analysis of Tunisian families with Usher syndrome type 1: Toward improving early molecular diagnosis. Mol. Vis. 22, 827 (2016).
4. Hope, C., Bundey, S., Proops, D. & Fielder, A. Usher syndrome in the city of Birmingham—Prevalence and clinical classification. Br. J. Ophthalmol. 81, 46–53 (1997).
5. Yan, D. et al. Mutation analysis in the long isoform of USH2A in American patients with Usher Syndrome type II. J. Hum. Genet. 54, 732–738 (2009).